Parabilis Medicines, Inc. (PBLS)

Company

Parabilis Medicines, Inc. (PBLS)

StatusJun 10, 2026
BiotechnologyBiotechnology
Initial Public Offering / IPOInitial Public Offering / IPO
IPO
Prospectus volume (424B4)670 m USD33,500,000 shares · 20 USD/share

We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. 

Former names

NameUntil
FOG PHARMACEUTICALS, INC.Dec 2, 2022

Chart/Sentiment

Financials

Parabilis Medicines, Inc. (PBLS)

Latest quarterly filing: 10-Q

Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.

Continue exploring

SPACSTAR Tools

Scroll to Top